Neda A. Moatamed, MD

Link to Neda Moatamed Publications >(Link is external) (Link opens in new window)

1. Li YR, Ochoa CJ, Zhu Y, Kramer A, Wilson M, Fang Y, Chen Y, Singh T, Di Bernardo G, Zhu E, Lee D, Moatamed NA, Bando J, Zhou JJ, Memarzadeh S, Yang L. Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. iScience. 2023 Sep 19;26(10):107952. doi: 10.1016/j.isci.2023.107952. eCollection 2023 Oct 20.
2. Moatamed NA, Vahdatshariatpanahi S, Gjertson DW, Sachs CR, Kang Y, Ostrzega N, Huang J, Memarzadeh S. Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers. PLoS One. 2023 Sep 19;18(9):e029136 doi: 10.1371/journal.pone.0291361. eCollection 2023.
3. Treece CLB, Filipek J, Makker J, Moatamed NA, Rodriguez EF. Accuracy of frozen section remote subspecialty consultation using real-time telepathology and whole-slide imaging in gynecologic cases. Am J Clin Pathol. 2023 Aug 28:aqad105. doi: 10.1093/ajcp/aqad105.
4. Kim TH, Rodriguez EF, Lim D, Moatamed NA. "Copy number alteration" as the sole molecular finding of a Thyroseq test is more commonly seen in Hurthle cell neoplasms. Diagn Cytopathol. 2023 Nov;51(11):705-711. doi: 10.1002/dc.25205.
5. Martel RA, Marsh L, Lai T, Rodriguez-Triana VM, Moatamed NA, Cohen J. Use of platinum-based chemotherapy and pembrolizumab to treat squamous cell carcinoma arising in a mature teratoma of the ovary in a pre-menopausal woman with negative response: A case report. Gynecol Oncol Rep. 2023 Apr 20;47:101192. doi: 10.1016/j.gore.2023.101192.
6. Moatamed NA, Barco AD, Yang SE, Ying Y, Zhang S, Rodriguez EF. Clinical history of female-to-male transgender patients is needed to avoid misinterpretation of cervical Papanicolaou tests. Cytopathology. 2023 Mar;34(2):120-129. doi: 10.1111/cyt.13199. Epub 2023 Jan 5.
7. Samiei A, Gjertson DW, Memarzadeh S, Konecny GE, Moatamed NA. Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors. Diagn Pathol. 2022 Sep 14;17(1):70. doi: 10.1186/s13000-022-01251-2.
8. Singh T, Neal A, Dibernardo G, Raheseparian N, Moatamed NA, Memarzadeh S. Efficacy of birinapant in combination with carboplatin in targeting platinumresistant epithelial ovarian cancers. Int J Oncol. 2022;60(3).
9. Young PA, Marquez-Garban DC, Noor ZS, Moatamed N, Elashoff D, Grogan T, Romero T, Sasano H, Saito R, Rausch R, Hamilton N, Dubinett SM, Garon EB, Pietras RJ. Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC. JTO Clin Res Rep. 2021;2(4):100150.
10. Mah V, Elshimali Y, Chu A, Moatamed NA, Uzzell JP, Tsui J, Schettler S, Shakeri H, Wadehra M. ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas. Sci Rep. 2021;11(1):11949.

• uclahealth.org/pathology
• breastcenter.ucla.edu(Link is external) (Link opens in new window)